Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Additive Potentiation of R334W-CFTR Function by Novel Small Molecules
Mafalda Bacalhau, Filipa C. Ferreira, Iris A. L. Silva, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 1, pp. 102-102
Open Access | Times Cited: 9

Showing 9 citing articles:

PTI-801 (posenacaftor) shares a common mechanism with VX-445 (elexacaftor) to rescue p.Phe508del-CFTR
Filipa C. Ferreira, Margarida D. Amaral, Mafalda Bacalhau, et al.
European Journal of Pharmacology (2024) Vol. 967, pp. 176390-176390
Open Access | Times Cited: 6
Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor
Filipa C. Ferreira, Camilla D. Buarque, Miquéias Lopes‐Pacheco
Molecules (2024) Vol. 29, Iss. 4, pp. 821-821
Open Access | Times Cited: 6
Rescue of Mutant CFTR Channel Activity by Investigational Co-Potentiator Therapy
Mafalda Bacalhau, Filipa C. Ferreira, Marcelo Folhadella M. F. Azevedo, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 82-82
Open Access
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Recent developments in cystic fibrosis drug discovery: where are we today?
Miquéias Lopes‐Pacheco, Amanda Winters, JaNise J. Jackson, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
Kathryn E. Oliver, Marianne S. Carlon, Nicoletta Pedemonte, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 14, pp. 1545-1565
Open Access | Times Cited: 12
Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies
Saba Anwar, Jingliang Peng, Kashif Rafiq Zahid, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 4, pp. 263-277
Open Access | Times Cited: 3
Cystic fibrosis cell models for high-throughput analysis and drug screening
Aidi Liu, Mithil Chokshi, Nghi Nguyen, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 4, pp. 716-724
Closed Access | Times Cited: 1
Direct access of 4-acyl-1,2,3-triazoles from acetophenones: a synthetic shortcut for novel p.Phe508del-CFTR traffic correctors
Marcelo Folhadella M. F. Azevedo, David C. Zeitune, Renan Lira de Farias, et al.
Journal of Molecular Structure (2024) Vol. 1321, pp. 139897-139897
Closed Access | Times Cited: 1
Targeting NHE6 gene expression identifies lysosome and neurodevelopmental mechanisms in a haploid in vitro cell model
Qing Wu, Li Ma, Lena Joesch-Cohen, et al.
Biology Open (2023) Vol. 12, Iss. 11
Open Access
Page 1

Scroll to top